Tomita, Yohei

写真a

Affiliation

School of Medicine, Department of Ophthalmology （Shinanomachi）

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)
Page Top ▲
 

Papers 【 Display / hide 】

  • Associations between fatty acid intake and diabetic retinopathy in a Japanese population

    Sasaki M., Yuki K., Hanyuda A., Yamagishi K., Motomura K., Kurihara T., Tomita Y., Mori K., Ozawa N., Ozawa Y., Sawada N., Negishi K., Tsubota K., Tsugane S., Iso H.

    Scientific Reports （Scientific Reports)  13 （ 1 ）  2023.12

    　View Summary

    Residents of Chikusei City, aged 40–74 years, underwent systemic and ophthalmological screening, and participants with diabetes were included in this analysis. Dietary intake was assessed using a food frequency questionnaire and calculated as a percentage of the total energy. The presence of diabetic retinopathy (DR) was defined as Early Treatment Diabetic Retinopathy Study levels ≥ 20 in either eye. The association between dietary fatty acid intake and DR has been examined in a cross-sectional study. Among the 647 diabetic participants, 100 had DR. The mean total fat and saturated fatty acid (SFA) intakes were 22.0% and 7.3% of the total energy intake, respectively. After adjusting for potential confounders, the highest quartiles of total fat and SFA intake were positively associated with the presence of DR compared with the lowest quartiles (odds ratios (95% confidence intervals), 2.61 (1.07–6.39), p for trend = 0.025, and 2.40 (1.12–5.17), p for trend = 0.013, respectively). No significant associations were found between DR prevalence and monounsaturated or unsaturated fatty acid intake. These results suggest that a high intake of fat and SFA may affect the development of DR, even in individuals whose total fat intake is generally much lower than that of Westerners.

  • Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?

    Lee D., Tomita Y., Negishi K., Kurihara T.

    Neural Regeneration Research （Neural Regeneration Research)  18 （ 7 ） 1495 - 1496 2023.07

    ISSN  16735374

  • Therapeutic roles of PPARα activation in ocular ischemic diseases

    Lee D., Tomita Y., Negishi K., Kurihara T.

    Histology and Histopathology （Histology and Histopathology)  38 （ 4 ） 391 - 401 2023.04

    ISSN  02133911

    　View Summary

    Ocular ischemia is one of the leading causes of blindness. It is related to various ocular diseases and disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma, and corneal injury. Ocular ischemia occurs due to an abnormal supply of oxygen and nutrients to the eye, resulting in ocular metabolic dysfunction. These changes can be linked with pathologic conditions in the eye, such as inflammation, neovascularization, and cell death, ultimately leading to vision loss. The current treatment care for ocular ischemia is limited. Peroxisome proliferator-activated recept or α (PPARα) i s a nucl ear recept or prot ei n functioning in regulating lipid metabolism, fatty acid oxidation, and glucose homeostasis. Recently, PPARα activation has been suggested as a useful therapeutic t arget i n t r eat i ng ocul ar i schemi a. However, i t s applications have not been well summarized. In this review, we cover an overview of the therapeutic roles of PPARα activation in various ocular ischemic conditions with recent experimental evidence and further provide clinical implications of its therapeutic applications. Our review will enable more approaches to comprehensively understand the therapeutic roles of PPARα activation for preventing ocular ischemic diseases.

  • Molecular and Cellular Regulations in the Development of the Choroidal Circulation System

    Imanishi S., Tomita Y., Negishi K., Tsubota K., Kurihara T.

    International Journal of Molecular Sciences （International Journal of Molecular Sciences)  24 （ 6 ）  2023.03

    ISSN  16616596

    　View Summary

    Disorders in the development and regulation of blood vessels are involved in various ocular disorders, such as persistent hyperplastic primary vitreous, familial exudative vitreoretinopathy, and choroidal dystrophy. Thus, the appropriate regulation of vascular development is essential for healthy ocular functions. However, regulation of the developing choroidal circulation system has not been well studied compared with vascular regulation in the vitreous and the retina. The choroid is a vascular-rich and uniquely structured tissue supplying oxygen and nutrients to the retina, and hypoplasia and the degeneration of the choroid are involved in many ocular disorders. Therefore, understanding the developing choroidal circulation system expands our knowledge of ocular development and supports our understanding of ocular disorders. In this review, we examine studies on regulating the developing choroidal circulation system at the cellular and molecular levels and discuss the relevance to human diseases.

  • Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration

    Lee D., Nakai A., Miwa Y., Negishi K., Tomita Y., Kurihara T.

    PeerJ （PeerJ)  11 2023.01

    　View Summary

    Background. Pathological choroidal neovascularization (CNV) is one of the major causes of visual impairment in neovascular age-related macular degeneration (AMD). CNV has been suppressed by using anti-vascular endothelial growth factor (VEGF) antibodies. However, some clinical cases have demonstrated the failure of anti-VEGF therapies. Furthermore, anti-VEGF agents might induce the development of ocular atrophy. Recently, peroxisome proliferator-activated receptor alpha (PPARα) activation using pemafibrate treatment was suggested as one of the promising therapeutic targets in the prevention of ocular ischemia. However, the preventive role of pemafibrate remains unclear in CNV. We aimed to examine the preventive role of pemafibrate on laser-induced pathological CNV. Methods. Adult male C57BL/6 mice were orally supplied pemafibrate (0.5 mg/kg) for four days, followed by laser irradiation. Then, pemafibrate was consecutively given to mice with the same condition. CNV was visualized with isolectin-IB4. The eye (retina and/or retinal pigment epithelium [RPE]-choroid), liver, and serum were used for biomolecular analyses. Results. We found that pemafibrate administration suppressed CNV volumes. Pemafibrate administration activated PPARα downstream genes in the liver and eye (especially, RPE-choroid). Furthermore, pemafibrate administration elevated serum fibroblast growth factor 21 levels and reduced serum levels of triglycerides. Conclusions. Our data suggest a promising pemafibrate therapy for suppressing CNV in AMD.

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Elucidation of the mechanisms of pathological myopia and development of new treatment focusing on PPARa

    2023.04
    -
    2025.03

    若手研究, Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2024

  • LECTURE SERIES, OPHTHALMOLOGY

    2024

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2023

Page Top ▲